Subtopic Deep Dive

Histone Acetylation in Enhancers
Research Guide

What is Histone Acetylation in Enhancers?

Histone acetylation at H3K27ac marks distinguishes active enhancers from poised ones, predicting developmental states and linking to transcriptional regulation in disease.

Creyghton et al. (2010) identified H3K27ac as a hallmark of active enhancers in embryonic stem cells, with 4343 citations. This mark correlates with enhancer activity and gene expression programs. Jin et al. (2010) detailed CBP/p300-mediated H3K27ac roles in nuclear receptor transactivation (861 citations).

Curated Papers

Key Challenges

Why It Matters

H3K27ac profiling predicts cellular states in cancer, identifying therapeutic targets like BET inhibitors targeting acetylated enhancers (Shu et al., 2016; 608 citations). In triple-negative breast cancer, BRD4 inhibition disrupts H3K27ac-dependent super-enhancers driving oncogenes (Donati et al., 2018; 681 citations). Epigenetic drugs modulating acetylation show clinical promise (Cheng et al., 2019; 1040 citations). SWI/SNF complexes regulate enhancer-mediated Myc expression in leukemia (Shi et al., 2013; 448 citations).

Key Research Challenges

Dynamic Enhancer Identification

Distinguishing active H3K27ac enhancers from poised states requires high-resolution mapping amid chromatin variability (Creyghton et al., 2010). Developmental and cancer contexts alter acetylation patterns dynamically. Integrating multi-omics data poses computational hurdles.

Therapeutic Targeting Specificity

Inhibitors like BET bromodomain blockers affect broad H3K27ac readers, causing resistance in cancers (Shu et al., 2016). Distinguishing cancer-specific enhancers from normal ones challenges selectivity. Clinical translation lags due to off-target effects (Cheng et al., 2019).

Acetylation-Degradation Crosstalk

Protein degradation pathways intersect with histone acetylation via ubiquitin ligases like TRIM24 at enhancers (Tsai et al., 2010). Quantifying degradation impacts on acetyl marks remains difficult. HDAC inhibitors alter dynamics unpredictably (Milazzo et al., 2020).

Essential Papers

Histone H3K27ac separates active from poised enhancers and predicts developmental state

Menno P. Creyghton, Albert W. Cheng, G. Grant Welstead et al. · 2010 · Proceedings of the National Academy of Sciences · 4.3K citations

Developmental programs are controlled by transcription factors and chromatin regulators, which maintain specific gene expression programs through epigenetic modification of the genome. These regula...

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Yuan Cheng, He Cai, Manni Wang et al. · 2019 · Signal Transduction and Targeted Therapy · 1.0K citations

Distinct roles of GCN5/PCAF‐mediated H3K9ac and CBP/p300‐mediated H3K18/27ac in nuclear receptor transactivation

Qihuang Jin, Li‐Rong Yu, Lifeng Wang et al. · 2010 · The EMBO Journal · 861 citations

BRD4 and Cancer: going beyond transcriptional regulation

Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi · 2018 · Molecular Cancer · 681 citations

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shaokun Shu, Charles Y. Lin, Housheng Hansen He et al. · 2016 · Nature · 608 citations

Epigenetic modifications of histones in cancer

Zibo Zhao, Ali Shilatifard · 2019 · Genome biology · 561 citations

Abstract The epigenetic modifications of histones are versatile marks that are intimately connected to development and disease pathogenesis including human cancers. In this review, we will discuss ...

Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated <i>Myc</i> regulation

Junwei Shi, Warren A. Whyte, Cinthya Zepeda‐Mendoza et al. · 2013 · Genes & Development · 448 citations

Cancer cells frequently depend on chromatin regulatory activities to maintain a malignant phenotype. Here, we show that leukemia cells require the mammalian SWI/SNF chromatin remodeling complex for...

Reading Guide

Foundational Papers

Start with Creyghton et al. (2010) for H3K27ac enhancer definition (4343 citations); Jin et al. (2010) for acetyltransferase mechanisms (861 citations); Shi et al. (2013) for cancer enhancer regulation (448 citations).

Recent Advances

Cheng et al. (2019) on epigenetic therapies (1040 citations); Donati et al. (2018) on BRD4 beyond transcription (681 citations); Milazzo et al. (2020) on HDAC evolution (364 citations).

Core Methods

ChIP-seq for H3K27ac profiling; BRD4 ChIP for reader mapping; PROTAC screens for degradation; RNA-seq integration for enhancer activity.

How PapersFlow Helps You Research Histone Acetylation in Enhancers

Discover & Search

Research Agent uses searchPapers and citationGraph to map H3K27ac literature from Creyghton et al. (2010, 4343 citations) hubs, revealing clusters around BET inhibitors. exaSearch uncovers enhancer acetylation in degradation contexts; findSimilarPapers expands from Shi et al. (2013) to SWI/SNF-Myc links.

Analyze & Verify

Analysis Agent applies readPaperContent to extract H3K27ac ChIP-seq methods from Jin et al. (2010), then verifyResponse with CoVe checks claims against 250M+ papers. runPythonAnalysis processes enhancer datasets for statistical validation of active vs. poised marks; GRADE scores evidence strength in cancer applications.

Synthesize & Write

Synthesis Agent detects gaps in H3K27ac degradation inhibitor links, flagging contradictions between BRD4 studies. Writing Agent uses latexEditText and latexSyncCitations for enhancer diagrams, latexCompile for manuscripts, exportMermaid for acetylation pathway graphs.

Use Cases

"Analyze H3K27ac ChIP-seq data from Creyghton 2010 to quantify active enhancers in ESCs."

Research Agent → searchPapers('Creyghton H3K27ac') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas/matplotlib on supplemental data) → statistical plots of active/poised ratios.

"Draft LaTeX review on BET inhibitors targeting H3K27ac enhancers in breast cancer."

Synthesis Agent → gap detection on Shu et al. (2016) → Writing Agent → latexEditText(draft) → latexSyncCitations(Shu/Donati) → latexCompile → PDF with enhancer figures.

"Find code for enhancer prediction models linked to histone acetylation papers."

Research Agent → paperExtractUrls('H3K27ac enhancer') → paperFindGithubRepo → Code Discovery → githubRepoInspect → validated scripts for ChIP-seq analysis.

Automated Workflows

Deep Research workflow scans 50+ H3K27ac papers via citationGraph from Creyghton et al. (2010), generating structured reports on enhancer-cancer links with GRADE scoring. DeepScan applies 7-step CoVe to verify BET inhibitor resistance mechanisms (Shu et al., 2016). Theorizer builds hypotheses on TRIM24 degradation at acetylated enhancers (Tsai et al., 2010).

Try Doxa for Histone Acetylation in Enhancers Research

Frequently Asked Questions

What defines active enhancers via histone acetylation?

H3K27ac marks active enhancers, separating them from poised ones and predicting developmental state (Creyghton et al., 2010).

What methods study H3K27ac in enhancers?

ChIP-seq maps H3K27ac genome-wide; CBP/p300 mediate deposition for transactivation (Jin et al., 2010). Integrates with RNA-seq for activity correlation.

What are key papers on this topic?

Creyghton et al. (2010, 4343 citations) foundational; Shu et al. (2016, 608 citations) on BET inhibitors; Cheng et al. (2019, 1040 citations) on therapies.